Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
eClinicalMedicine (2022) - Comments
pubmed: 36188435  doi: 10.1016/j.eclinm.2022.101680  issn: 2589-5370 

Yuemiao Zhang, Xupu Ma, Guanghong Yan, Ying Wu, Yanli Chen, Zumi Zhou, Na Wan, Wei Su, Feng-Wei Liu, Mu-Xian Dai, Mei Yang, Chunmei Li, Xuanjing Yu, Liang Zhang, Zhongfang Wang, Tai-Cheng Zhou, Dingyun You, Jia Wei, Zijie Zhang